Oxford Biomedica PLC Director Dealings / Market Share Sale and Purchase (0074L)
13 July 2017 - 9:38PM
UK Regulatory
TIDMOXB
RNS Number : 0074L
Oxford Biomedica PLC
13 July 2017
Director Dealings / Market Share Sale and Purchase
Oxford, UK - 13 July 2017: Oxford BioMedica plc ("Oxford
BioMedica" or "the Company") (LSE: OXB), a leading gene and cell
therapy group, was informed that on 13 July 2017 Tim Watts, Chief
Financial Officer, exercised options over 1,325,035 ordinary shares
of 1p each ("Ordinary Shares") in the Company. The options, which
were exercisable at nil cost, were originally granted in June 2014
under the Company's Deferred Bonus Plan.
Following the exercise Mr Watts holds 8,720,159 ordinary shares
of 1p each ("Ordinary Shares") in the Company, 0.28% of the
Company's issued share capital.
The issued share capital of the Company is 3,089,030,365 1p
ordinary shares.
-Ends-
For further information,
please contact:
Oxford BioMedica plc: Tel: +44 (0)1865
John Dawson, Chief Executive 783 000
Officer
Tim Watts, Chief Financial
Officer
Financial and corporate communications Tel: +44 (0)20 3709
enquiries: 5700
Consilium Strategic Communications
Mary-Jane Elliott/Matthew
Neal/Chris Welsh/Laura Thornton
Notes for editors
About Oxford BioMedica(R)
Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy
company focused on developing life changing treatments for serious
diseases. Oxford BioMedica and its subsidiaries (the "Group") have
built a sector leading lentiviral vector delivery platform
(LentiVector(R) ) through which the Group develops in vivo and ex
vivo products both in-house and with partners. The Group has
created a valuable proprietary portfolio of gene and cell therapy
product candidates in the areas of oncology, ophthalmology and CNS
disorders. The Group has also entered into a number of
partnerships, including with Novartis, Sanofi, GSK, and Immune
Design, through which it has long-term economic interests in other
potential gene and cell therapy products. Oxford BioMedica is based
across several locations in Oxfordshire, UK and employs more than
250 people. Further information is available at
www.oxfordbiomedica.co.uk.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCRJMBTMBJBBFR
(END) Dow Jones Newswires
July 13, 2017 07:38 ET (11:38 GMT)
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Apr 2024 to May 2024
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From May 2023 to May 2024